盤前公告 | 信達生物折讓4.87%配售5200萬股股份
uSMART盈立智投1月15日消息,週五港股盤前,信達生物發佈《根據一般授權配售新股份》公告稱,於2021年1月15日(交易時段前),本公司與聯席配售代理訂立配售協議,據此,本公司同意委任聯席配售代理,及聯席配售代理同意作爲配售代理行事,以作爲本公司的代理根據配售協議所載的條款並在其條件規限下,促使承配人(否則自行)以配售價購買52,000,000股配售股份。
配售事項所得款項總額預期約爲47.27億港元。
每股配售股份90.9港元,相當於:(i)股份於2021年1月14日(即配售協議日期前一天)在聯交所所報的收市價每股95.55港元折讓約4.87%;及(ii)股份於緊接配售協議日期前連續五個交易日在聯交所所報的平均收市價每股89.23港元溢價約1.87%。
點擊可跳轉閱讀《信達生物根據一般授權配售新股份》公告原文件PDF。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.